Q4 2024 Catalyst Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Catalyst Pharmaceuticals Inc (CPRX) reported a record revenue growth of 23.5% year over year, reaching $491.7 million for 2024.
- The company ended the year with a robust cash position of $517.6 million and no debt, enhancing its capacity to invest in strategic growth opportunities.
- FirdApps, the only evidence-based treatment for Lambert-Eaton Myasthenic syndrome, showed strong performance with a 18.3% year-over-year growth in Q4 2024.
- Agamri, launched in March 2024, gained significant traction with full-year net product revenue of $46 million, surpassing revised guidance.
- Catalyst Pharmaceuticals Inc (CPRX) secured a favorable resolution to the Teva patent litigation, prohibiting generic entry until February 2035, reinforcing FirdApps's intellectual property strength.
- FICOMPA's net product revenue is expected to decline gradually in the second half of 2025 due to the anticipated loss of exclusivity and generic market entry.
- The company anticipates an increase in SG&A expenses in 2025, driven by increased headcount and the launch of separate commercial and medical field forces.
- Gross-to-net deductions for FICOMPA therapy increased due to higher costs tied to arrangements with distributors and government agencies.
- The Inflation Reduction Act is expected to impact gross-to-net for FirdApps, with an anticipated increase in deductions over the coming years.
- The crowded Duchenne muscular dystrophy (DMD) landscape has created a competition for share of voice, potentially delaying Agamri's adoption for some patients.
Greetings and welcome to the Catalyst Pharmaceuticals fourth quarter in full year 2024 financial results conference call. (Operator Instructions).
As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mike Tow. Thank you, and you may begin.
Good morning everyone and thank you for joining our conference call to discuss Catalyst's fourth quarter and full year 2024 financial results and business highlights. Leading the call today is Richard Daly; Catalyst's President and Chief Executive Officer.
We're also joined by Jeff Del Carmen; our Chief Commercial Officer. Further for the Q&A session, Dr. Jeff Del Carmen; our Chief Operating Officer and Chief Scientific Officer, and Dr. Gary Ingenito; our chief medical and regulatory officer, will be available for questions. Before we begin, I would like to remind you that in our remarks this morning and in the Q&A session, we will make statements about
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
